Clinical Efficacy of Dienogest and Levonorgestrel-Releasing Intrauterine System in the Treatment of Adenomyosis

Objective: To compare the clinical efficacy and adverse reactions of dienogest and levonorgestrel-releasing intrauterine system in the treatment of adenomyosis. Methods: A total of 60 cases of adenomyosis admitted to Dezhou Women and Children’s Hospital from January 2020 to October 2021 were selected and randomly divided into two groups (Group A and Group B), which were initiated on dienogest and levonorgestrel-releasing intrauterine system, respectively. The therapeutic effects and adverse reactions of the two groups were analyzed. Results: After 6 months of treatment, the uterine volume in the LNG-IUS group reduced slightly compared with that before treatment, with no statistical significance (p > 0.05), while that in the DNG group increased slightly compared with that before treatment, with no statistical significance (p > 0.05). After 6 months of treatment, the hemoglobin of patients in both groups increased compared with that before treatment; there was no significant difference in the DNG group (p > 0.05), but there was significant difference in the LNG-IUS group (p < 0.01). After 6 months of treatment, the VAS scores of the two groups were significantly lower than those before treatment (p < 0.01); the serum CA125 level in both groups decreased significantly compared with that before treatment (p < 0.01). Conclusion: Mirena (levonorgestrel-releasing intrauterine system) has better therapeutic effect on adenomyosis and fewer adverse reactions than deinogest.